KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Depreciation and Depletion: 2010-2022

Historic Depreciation and Depletion for TherapeuticsMD (TXMD) over the last 11 years, with Dec 2022 value amounting to $200,000.

  • TherapeuticsMD's Depreciation and Depletion rose 200.00% to $200,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $700,000, marking a year-over-year increase of 75.00%. This contributed to the annual value of $600,000 for FY2022, which is 50.00% up from last year.
  • Latest data reveals that TherapeuticsMD reported Depreciation and Depletion of $200,000 as of Q4 2022, which was down 0.00% from $200,000 recorded in Q3 2022.
  • TherapeuticsMD's Depreciation and Depletion's 5-year high stood at $200,000 during Q2 2020, with a 5-year trough of -$200,000 in Q4 2021.
  • Over the past 3 years, TherapeuticsMD's median Depreciation and Depletion value was $200,000 (recorded in 2022), while the average stood at $158,250.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first spiked by 200.50% in 2020, then tumbled by 200.00% in 2021.
  • TherapeuticsMD's Depreciation and Depletion (Quarterly) stood at $59,989 in 2018, then spiked by 193.80% to $176,250 in 2019, then climbed by 13.48% to $200,000 in 2020, then slumped by 200.00% to -$200,000 in 2021, then surged by 200.00% to $200,000 in 2022.
  • Its Depreciation and Depletion stands at $200,000 for Q4 2022, versus $200,000 for Q3 2022 and $200,000 for Q2 2022.